Oriental Biotech Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
- Paid Up Capital ₹ 2.62 M
- Company Age 28 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 17.46%
- Profit Growth 95.48%
- Ebitda 7.29%
- Net Worth 6.45%
- Total Assets 4.85%
About Oriental Biotech
Oriental Biotech Limited (OBL) is a Public Limited Indian Non-Government Company incorporated in India on 23 September 1996 and has a history of 28 years and five months. Its registered office is in Bangaluru, Karnataka, India.
The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 2.62 M, as per Ministry of Corporate Affairs (MCA) records.
Atmaram Modi, Atul Modi, Anup Modi, and Two other members serve as directors at the Company.
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U85110KA1996PLC021173
- Company No.
021173
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
23 Sep 1996
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Agriculture
Who are the key members and board of directors at Oriental Biotech?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Atul Modi  | Managing Director | 23-Sep-1996 | Current |
| Anup Modi | Managing Director | 23-Sep-1996 | Current |
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Atmaram Modi | Director | 23-Sep-1996 | Current |
| Seema Modi | Director | 02-Jun-2022 | Current |
| Shalini Modi | Director | 02-Jun-2022 | Current |
Financial Performance of Oriental Biotech.
Oriental Biotech Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 17.46% increase. The company also saw a substantial improvement in profitability, with a 95.48% increase in profit. The company's net worth moved up by a moderate rise of 6.45%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Oriental Biotech?
In 2019, Oriental Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Oriental Biotech?
Unlock and access historical data on people associated with Oriental Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Oriental Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Oriental Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
